Fulcrum Therapeutics (NASDAQ:FULC) Announces Earnings Results, Misses Expectations By $0.10 EPS

Fulcrum Therapeutics (NASDAQ:FULC) posted its earnings results on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10), FiscalAI reports.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC opened at $3.58 on Friday. Fulcrum Therapeutics has a one year low of $2.83 and a one year high of $15.74. The business’s 50-day simple moving average is $3.99 and its 200 day simple moving average is $6.93. The stock has a market cap of $238.54 million, a price-to-earnings ratio of -3.11 and a beta of 3.01.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on FULC shares. Truist Financial downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research note on Tuesday, June 2nd. JPMorgan Chase & Co. downgraded shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Wednesday, June 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th. Citigroup lowered shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a report on Tuesday, June 2nd. Finally, HC Wainwright cut shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $8.20.

Insider Buying and Selling

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the sale, the director owned 10,927 shares in the company, valued at $39,883.55. This trade represents a 62.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Quarry LP increased its stake in shares of Fulcrum Therapeutics by 354.8% in the fourth quarter. Quarry LP now owns 17,165 shares of the company’s stock worth $194,000 after buying an additional 13,391 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Fulcrum Therapeutics in the fourth quarter valued at $175,000. Man Group plc bought a new position in Fulcrum Therapeutics during the 4th quarter valued at $173,000. EntryPoint Capital LLC bought a new position in Fulcrum Therapeutics during the 4th quarter valued at $171,000. Finally, Cubist Systematic Strategies LLC bought a new position in Fulcrum Therapeutics during the 1st quarter valued at $164,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.